A new scoring system using multiple immunohistochemical markers for diagnosis of uterine smooth muscle tumors

Journal of Cellular and Molecular Medicine

Volumn 10, Issue 1, 2006, Pages 197-205

  Rath Wolfson, Lea ^a,c   Rosenblat, Yevgenia ^a,c   Halpern, Marisa ^a,c   Herbert, M ^b,c   Hammel, I ^c   Gal, Rivka ^a,c   Leabu, M ^d,e   Koren, Rumelia ^a,c  

^a HASHARON HOSPITAL   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

Author keywords

Atypical leiomyomas; Cellular leiomyomas; Immunohistochemistry; Leiomyosarcomas; Score; Usual leiomyomas; Uterus

Indexed keywords

CELL NUCLEUS ANTIGEN; KI 67 ANTIGEN; NUCLEAR PROTEIN; NUCLEOLAR ORGANIZER REGION ASSOCIATED PROTEINS; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ARTICLE; EVALUATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MUSCLE TUMOR; UTERUS CANCER;

ANTIGENS, NUCLEAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RESEARCH DESIGN; SMOOTH MUSCLE TUMOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 33748362842     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2006.tb00300.x     Document Type: Article

References (24)

1. Zhai YL, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, Fujii S. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999; 18: 20-8.
2. Zhai YL, Nikaido T, Toki T, Shiozawa A, Orii A, Fujii S. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer 1999; 80: 1658-64.
3. rd, Howard DR, Andersen WA, Figge DC. Uterine smooth-muscle tumors of uncertain malignant potential. Obstet Gynecol. 1994; 83: 1015-20.
4. th ed. Vol. 1, Edinburgh: Churchill Livingstone, 1995: 542-73.
5. Layfield LJ, Liu K, Dodge R, Barsky SH. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology. Arch Pathol Lab Med. 2000; 124: 221-7.
6. Donhuijsen K. Mitosis counts: reproducibility and significance in grading of malignancy. Hum Pathol. 1986; 17: 1122-5.
7. Kenipson RL. Editorial: Mitosis counting-II. Hum Pathol. 1976; 7: 482-3.
8. Ellis PS, Whitehead R. Mitosis counting-a need for reappraisal. Hum Pathol. 1981; 12: 3-4.
9. Silverberg SG. Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumors of the uterus. Hum Pathol. 1976; 7: 451-4.
10. Kempson RL, Bari W. Uterine sarcomas. Classification, diagnosis, and prognosis. Hum Pathol. 1970; 1: 331-49.
11. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994; 18: 535-58.
12. Mudigdo A, Niwa K, Morishita S, Hashimoto M, Murase T, Tamaya T. Silver-stained nucleolar organizer regions in the uterine myomatous tumors. Cancer Lett. 1996; 107: 273-5.
13. Boquist LL. Nucleolar organizer regions in uterine sarcomas. Virchows Arch A Pathol Anat Histopathol. 1992; 420: 353-8.
14. Sprogoe-Jakobsen S, Holund B. Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus). APMIS. 1996; 104: 705-8.
15. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol. 1995; 14: 134-42.
16. Nordal RR, Kristensen GB, Stenwig AE, Trope CG, Nesland JM. Immunohistochemical analysis of p53 protein in uterine sarcomas. Gynecol Oncol. 1998; 70: 45-8.
17. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001; 32: 984-7.
18. Soini Y, Paakko P. Bcl-2 is preferentially expressed in tumours of muscle origin but is not related to p53 expression. Histopathology 1996; 28: 141-5.
19. Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet JJ. Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J. 1986; 18: 5-14.
20. Gal R, Rath-Wolfson L, Rosenblatt Y, Halpern M, Schwartz A, Koren R. An improved technique for mitosis counting. Int J Surg Pathol. 2005; 13: 161-5.
21. Kaklamanis L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I, Biddolph S, Tsiotos P, Mortensen N, Gatter KC, Harris AL. Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. Br J Cancer 1998; 77: 1864-9.
22. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994; 54: 2095-7.
23. de Vos S, Wilczynski SP, Fleischhacker M, Koeffler P. p53 alterations in uterine leiomyosarcomas versus leiomyomas. Gynecol Oncol. 1994; 54: 205-8.
24. Niemann TH, Raab SS, Lenel JC, Rodgers JR, Robinson RA. p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol. 1995; 26: 375-9.